TRUMENBA targets a protein found in over 95% of bacteria that cause Meningitis B. It works by helping the body make antibodies (the body’s natural defenses), which protect individuals against this disease. These antibodies kill the bacteria that cause Meningitis B.
If a vaccinated person comes into contact with the bacteria that cause this disease, their body is usually ready to destroy them.
Your healthcare professional will inject TRUMENBA into the upper arm muscle as a single injection of 0.5 mL, on two or three separate occasions.
NACI recommends that TRUMENBA may be considered as an option for individuals 10–25 years of age who are not at higher risk of meningococcal disease than the general population, in a 2-dose schedule (0 and 6 months), to reduce the risk of invasive serogroup B meningococcal disease.
Individuals at increased risk of IMD may include persons with functional or anatomic asplenia, including sickle cell disease; persons with congenital complement, properdin, factor D or primary antibody deficiencies; persons with acquired complement deficiency due to receipt of the terminal complement inhibitor eculizumab and individuals with HIV.